Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of ACADIA Pharmaceuticals -- a clinical-stage biopharmaceutical company with a focus on central nervous system disorders -- skyrocketed as much as 32% after reporting data from its late-stage Parkinson's disease psychosis study with Pimavanserin.
So what: At the American Academy of Neurology annual meeting, ACADIA noted that Pimavanserin met the primary endpoint of the study by demonstrating "highly significant antipsychotic efficacy." Pimavanserin also met its secondary endpoint of motoric tolerability as measured by the Unified Parkinson's Disease Rating Scale, with the Pimavanserin arm demonstrating twice as much clinical global impression improvement as the control arm. The drug was well tolerated by patients, with urinary tract infections being the most common adverse event.
Now what: While it's impossible to tell if this will net Pimavanserin an approval from the FDA, I believe it undoubtedly gives the company enough fuel to file for a new drug application sometime in the next quarter or two. However, given the amazing run ACADIA's already had, I'm a bit leery about suggesting the stock could have further upside from here, and would patiently wait for the FDA panel's review of Pimavanserin before picking a side.
Craving more input? Start by adding ACADIA Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.
While you can certainly make huge gains in biotechs like ACADIA, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why ACADIA Pharmaceuticals Shares Soared originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.